New figures have confirmed that the UK’s biotech sector received a massive boost from the COVID-19 pandemic last year, with investment levels soaring to £2.8 billion ($3.8 billion) from a l
In the last few years, biopharma companies focusing on psychedelic medicines have been springing up like mushrooms – magic or otherwise – and venture capital money is starting to follow.
Israel’s specialist venture capital firm, Olive Tree Ventures (OTV) has closed a fund worth $170 million, with plans to expand its portfolio of digital health firms.
Trans-Atlantic biotech venture capital firm SR One has completed its spin-out from GlaxoSmithKline and closed its first fund with $500m in its coffers.
Ireland-based Fountain Healthcare Partners has raised another €125 million ($131 million) for its third life sciences fund – 25% ahead of its target – and says it will pump most of the mone
For a long time, venture capital (VC) firms have been controlled mainly by men. But things are changing and women are becoming more influential in life sciences VCs, with an increase in bu